Literature DB >> 16972122

Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies.

Hubertus Köller, Michael Schroeter, Heinrich Feischen, Hans-Peter Hartung, Bernd C Kieseier.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16972122     DOI： 10.1007/s00415-006-0258-0

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  10 in total

Review 1.  The pathogenesis of CIDP: rationale for treatment with immunomodulatory agents.

Authors:  Klaus V Toyka; Ralf Gold
Journal:  Neurology       Date:  2003-04-01       Impact factor: 9.910

Review 2.  Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force.

Authors: 
Journal:  Neurology       Date:  1991-05       Impact factor: 9.910

Review 3.  Chronic inflammatory demyelinating polyneuropathy.

Authors:  Hubertus Köller; Bernd C Kieseier; Sebastian Jander; Hans-Peter Hartung
Journal:  N Engl J Med       Date:  2005-03-31       Impact factor: 91.245

4.  Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion.

Authors:  A Gardulf; L Hammarström; C I Smith
Journal:  Lancet       Date:  1991-07-20       Impact factor: 79.321

5.  Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home.

Authors:  Uwe Nicolay; Peter Kiessling; Melvin Berger; Sudhir Gupta; Leman Yel; Chaim M Roifman; Ann Gardulf; Florian Eichmann; Stefan Haag; Cordula Massion; Hans D Ochs
Journal:  J Clin Immunol       Date:  2006-01       Impact factor: 8.317

6.  The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy.

Authors:  H M Chapel; G P Spickett; D Ericson; W Engl; M M Eibl; J Bjorkander
Journal:  J Clin Immunol       Date:  2000-03       Impact factor: 8.317

Review 7.  Intravenous immunoglobulin treatment of neurological autoimmune diseases.

Authors:  M Stangel; H P Hartung; P Marx; R Gold
Journal:  J Neurol Sci       Date:  1998-01-08       Impact factor: 3.181

8.  Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies.

Authors:  I S J Merkies; P I M Schmitz; F G A van der Meché; J P A Samijn; P A van Doorn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-05       Impact factor: 10.154

Review 9.  Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system.

Authors:  Bernd C Kieseier; Reinhard Kiefer; Ralf Gold; Bernhard Hemmer; Hugh J Willison; Hans-Peter Hartung
Journal:  Muscle Nerve       Date:  2004-08       Impact factor: 3.217

Review 10.  Intravenous immunoglobulin in autoimmune neuromuscular diseases.

Authors:  Marinos C Dalakas
Journal:  JAMA       Date:  2004-05-19       Impact factor: 56.272
  10 in total
  14 in total

Review 1.  [Administration of intravenous immunoglobulins in neurology. An evidence-based consensus: update 2010].

Authors:  M Stangel; R Gold
Journal:  Nervenarzt       Date:  2011-04       Impact factor: 1.214

2.  New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins.

Authors:  Martin Stangel
Journal:  Ther Adv Neurol Disord       Date:  2008-09       Impact factor: 6.570

Review 3.  Subcutaneous immunoglobulin: opportunities and outlook.

Authors:  S Misbah; M H Sturzenegger; M Borte; R S Shapiro; R L Wasserman; M Berger; H D Ochs
Journal:  Clin Exp Immunol       Date:  2009-12       Impact factor: 4.330

4.  Improvement of quality of life in patients with chronic inflammatory demyelinating polyneuropathy shifting from 16 to 20% subcutaneous immunoglobulins.

Authors:  Dario Cocito; Ilaria Paolasso; Erdita Peci; Emanuela Spagone; Leonardo Lopiano
Journal:  Neurol Sci       Date:  2013-04-11       Impact factor: 3.307

5.  Immunoglobulin therapy for refractory Crohn's disease.

Authors:  Shailja Shah; Jonathan Terdiman; Katherine Gundling; Uma Mahadevan
Journal:  Therap Adv Gastroenterol       Date:  2014-03       Impact factor: 4.409

6.  Subcutaneous immunoglobulin in CIDP and MMN: a short-term nationwide study.

Authors:  Dario Cocito; Aristide Merola; Erdita Peci; Anna Mazzeo; Raffaella Fazio; Ada Francia; Paola Valentino; Rocco Liguori; Massimiliano Filosto; Gabriele Siciliano; Angelo Maurizio Clerici; Stefania Lelli; Girolama Alessandra Marfia; Giovanni Antonini; Ilaria Cecconi; Eduardo Nobile-Orazio; Leonardo Lopiano
Journal:  J Neurol       Date:  2014-08-23       Impact factor: 4.849

Review 7.  Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies.

Authors:  Verena I Leussink; Hans-Peter Hartung; Bernd C Kieseier; Mark Stettner
Journal:  Ther Adv Neurol Disord       Date:  2016-04-06       Impact factor: 6.570

8.  Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins.

Authors:  Mohamed Mahdi-Rogers; Yusuf A Rajabally
Journal:  Biologics       Date:  2010-03-24

Review 9.  [The significance of intravenous immunoglobulin in treatment of immune-mediated polyneuropathies].

Authors:  M Stangel; H-P Hartung; R Gold; B C Kieseier
Journal:  Nervenarzt       Date:  2009-06       Impact factor: 1.214

10.  Subcutaneous immunoglobulin administration: an alternative to intravenous infusion as adjuvant treatment for dermatomyositis?

Authors:  Nicolas Schleinitz; Estelle Jean; Lucas Benarous; Karin Mazodier; Dominique Figarella-Branger; Emmanuelle Bernit; Véronique Veit; Gilles Kaplanski; Jean-Robert Harle
Journal:  Clin Rheumatol       Date:  2008-05-08       Impact factor: 2.980
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.